Literature DB >> 27747589

Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma.

Lei Wang1, Yu Wang2, Peng-Ping Li3, Rui Wang1, Yue Zhu1, Fang Zheng1, Lin Li1, Jiu-Jie Cui4, Li-Wei Wang5,6.   

Abstract

SAV1 is a human homolog of salvador that contains two protein-protein interaction modules known as WW domains and acts as a scaffolding protein for Hpo and Warts. SAV1 is known to be a tumor suppressor, but its clinical and prognostic implications remain elusive. This study aimed at evaluating the prognostic significance and associated expression of SAV1 in pancreatic ductal adenocarcinoma (PDAC) patients. The expression of SAV1 in tissue specimens of PDAC patients were assayed with immunohistochemistry on a tissue microarray. The correlations between SAV1 expression and clinicopathological characteristics were analyzed by Pearson's chi-square test, Fisher's exact test, and Spearman's rank. The prognostic factors for overall survival were analyzed by univariate and multivariate Cox regression. The percentage of SAV1 expression in PDAC (50.6 %) was significantly lower than those in paratumor tissues (69.9 %) (P = 0.017). Expression of SAV1 was only significantly correlated with histological differentiation (P = 0.025) and N classification (P = 0.009). On multivariate analysis, elevated expression of SAV1 and N0 was a significant favorable prognostic factor of OS. Our study demonstrated for the first time that lower expression of SAV1 might be involved in the progression of PDAC, suggesting that SAV1 may be a potential prognostic marker and target for PDAC therapy.

Entities:  

Keywords:  Immunohistochemistry; Pancreatic ductal adenocarcinoma; Prognosis; SAV1

Year:  2016        PMID: 27747589     DOI: 10.1007/s13277-016-5457-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  Hippo signaling regulates pancreas development through inactivation of Yap.

Authors:  Nicholas M George; Caroline E Day; Brian P Boerner; Randy L Johnson; Nora E Sarvetnick
Journal:  Mol Cell Biol       Date:  2012-10-15       Impact factor: 4.272

Review 3.  The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease.

Authors:  Xaralabos Varelas
Journal:  Development       Date:  2014-04       Impact factor: 6.868

4.  The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis.

Authors:  Kwang-Pyo Lee; Joo-Hyeon Lee; Tae-Shin Kim; Tack-Hoon Kim; Hee-Dong Park; Jin-Seok Byun; Min-Chul Kim; Won-Il Jeong; Diego F Calvisi; Jin-Man Kim; Dae-Sik Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

Review 5.  The Hippo pathway in biological control and cancer development.

Authors:  Siew Wee Chan; Chun Jye Lim; Liming Chen; Yaan Fun Chong; Caixia Huang; Haiwei Song; Wanjin Hong
Journal:  J Cell Physiol       Date:  2011-04       Impact factor: 6.384

6.  Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver.

Authors:  Li Lu; Ying Li; Soo Mi Kim; Wouter Bossuyt; Pu Liu; Qiong Qiu; Yingdi Wang; Georg Halder; Milton J Finegold; Ju-Seog Lee; Randy L Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

7.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

8.  salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines.

Authors:  Nicolas Tapon; Kieran F Harvey; Daphne W Bell; Doke C R Wahrer; Taryn A Schiripo; Daniel A Haber; Iswar K Hariharan
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

9.  Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma.

Authors:  Keiko Matsuura; Chisato Nakada; Mizuho Mashio; Takahiro Narimatsu; Taichiro Yoshimoto; Masato Tanigawa; Yoshiyuki Tsukamoto; Naoki Hijiya; Ichiro Takeuchi; Takeo Nomura; Fuminori Sato; Hiromitsu Mimata; Masao Seto; Masatsugu Moriyama
Journal:  BMC Cancer       Date:  2011-12-20       Impact factor: 4.430

10.  Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.

Authors:  Meiyuan Chen; Min Wang; Simiao Xu; Xingjun Guo; Jianxin Jiang
Journal:  Oncotarget       Date:  2015-12-29
View more
  4 in total

1.  SAV1 represses the development of human colorectal cancer by regulating the Akt-mTOR pathway in a YAP-dependent manner.

Authors:  Jianwu Jiang; Wei Chang; Yang Fu; Yongshun Gao; Chunlin Zhao; Xiefu Zhang; Shuijun Zhang
Journal:  Cell Prolif       Date:  2017-06-15       Impact factor: 6.831

2.  A WW Tandem-Mediated Dimerization Mode of SAV1 Essential for Hippo Signaling.

Authors:  Zhijie Lin; Ruiling Xie; Kunliang Guan; Mingjie Zhang
Journal:  Cell Rep       Date:  2020-09-08       Impact factor: 9.423

3.  Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.

Authors:  Aleksandra Toloczko; Fusheng Guo; Hiu-Fung Yuen; Qing Wen; Stephen A Wood; Yan Shan Ong; Pei Yi Chan; Asfa Alli Shaik; Jayantha Gunaratne; Mark J Dunne; Wanjin Hong; Siew Wee Chan
Journal:  Cancer Res       Date:  2017-07-18       Impact factor: 12.701

Review 4.  Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature.

Authors:  Anello Marcello Poma; Liborio Torregrossa; Rossella Bruno; Fulvio Basolo; Gabriella Fontanini
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.